Storia in 8 fonti

Revolution Medicines starts shipping experimental pancreatic cancer drug

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Raccontata dapbs.orgstatnews.combiopharmadive.comfiercebiotech.comendpoints.newsbenzinga.comhindustantimes.compharmaceutical-technology.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.com2 g fa

Practice-changing results reported for Revolution Medicines pancreatic cancer drug

Revolution Medicines' daraxonrasib, a targeted oral therapy for pancreatic cancer, roughly doubled patient survival versus standard chemotherapy in a Phase trial presented at ASCO 2026 and published simultaneously in the New England Journal of Medicine. For biotech and oncology investors, this is the first meaningful efficacy signal in a notoriously treatment-resistant indication, likely to accelerate M&A interest and pipeline repositioning toward RAS-targeted agents.

Leggi questa versione → originale

benzinga.com1 g fa

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits

Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

Leggi questa versione → originale

biopharmadive.com2 g fa

‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

Leggi questa versione → originale

hindustantimes.com19 h fa

Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

Revolution Medicines' daraxonrasib extends median survival to 13.2 months in pancreatic cancer via a molecular glue approach targeting RAS mutations. For biotech strategists and tech leaders, the molecular glue approach demonstrates advances in structure-based drug design, opening new R&D paradigms in precision medicine.

Leggi questa versione → originale

endpoints.news2 g fa

Yes, Revolution Medicine's pancreatic cancer data is that good

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.

Leggi questa versione → originale

pbs.org3 g fa

Pancreatic cancer is deadly and difficult to treat. A new pill could change that

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Leggi questa versione → originale

Timeline cronologica

1. sabato 30 maggio 2026·pbs.org
   

   Pancreatic cancer is deadly and difficult to treat. A new pill could change that

   The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

2. sabato 30 maggio 2026·statnews.com
   

   Revolution Medicines starts shipping experimental pancreatic cancer drug

   CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

3. domenica 31 maggio 2026·biopharmadive.com
   

   ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

   Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

4. domenica 31 maggio 2026·fiercebiotech.com
   

   ASCO: Revolution Medicines confident in RAS leadership as rivals square up

   This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…

5. domenica 31 maggio 2026·statnews.com
   

   Practice-changing results reported for Revolution Medicines pancreatic cancer drug

   Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.

6. domenica 31 maggio 2026·endpoints.news
   

   Yes, Revolution Medicine's pancreatic cancer data is that good

   When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints…

7. lunedì 1 giugno 2026·benzinga.com
   

   Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits

   Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

8. lunedì 1 giugno 2026·hindustantimes.com
   

   Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

   While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News

9. lunedì 1 giugno 2026·pharmaceutical-technology.com
   

   ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

   The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

10. martedì 2 giugno 2026·hindustantimes.com
    

    Scientifically Speaking: A pill takes on pancreatic cancer

    For decades, the molecular switch that drives most pancreatic cancers was ‘undruggable’. No longer. A new drug has now nearly doubled how long patients live.